

Note: This document is a translation of the original Japanese version and provided for reference purposes only. In the event of any discrepancy between the Japanese original and this English translation, the Japanese original shall prevail.

Press Release



ASKA Obtains Manufacturing and Marketing Approval for Oral Contraceptive Slinda® 28 Tablets in Japan

TOKYO, May 19, 2025 – ASKA Pharmaceutical Co., Ltd. (Head Office: Minato-ku, Tokyo/ President, Representative Director: Sohta Yamaguchi, hereinafter “ASKA”), a subsidiary of ASKA Pharmaceutical Holdings Co., Ltd. (TSE:4886), announced that ASKA has obtained the manufacturing and marketing approval for Slinda® 28 Tablets (development code: LF111/generic name: drospirenone) in Japan today. The launch of this product is scheduled for July 2025.

This drug is a progestogen-only oral contraceptive (POP: Progestogen-Only Pill) containing drospirenone, which was introduced and developed by ASKA in Japan with the aim of expanding women's health options. In January 2020, ASKA acquired exclusive rights to develop and market the Product for the territories of Japan and the Republic of Korea from Insud Pharma (Head Office: Madrid, Spain). On June 24, 2024, the Company announced the “ASKA Pharmaceutical Files an Application for Manufacturing and Marketing Approval for LF111 in Japan.”

Currently, the Combined Oral Contraceptive Pill (COCP), which contains two types of female hormones, synthetic estrogen and progestin, is used as an oral contraceptive in Japan. This drug, a progestogen-only pill (POP) containing drospirenone, is approved in 62 foreign countries (as of January 2025). According to the World Health Organization guidelines, POP carries a lower risk of venous thromboembolism than COCP and is more highly recommended than COCP for smokers, obese women, women with hypertension or valvular disease, or those with a history of deep vein thrombosis or pulmonary embolism.

ASKA will continue to address women's health issues in earnest and contribute to society by providing pharmaceutical products that help solve problems at every stage of life.

Overview of Slinda® 28 Tablets

Product name: Slinda® 28 Tablets

Generic name: drospirenone

Indication: Contraceptive

Dosage and Administration : One tablet a day is orally administered at a specified time every day. The

drug is to be taken in the specified order (Beginning with the white tablets) for 28 consecutive days. One administration cycle is to be 28 days, and start the next administration cycle on the 29th day. Repeat the above administration cycle as indicated.

About Insud Pharma

Insud Pharma (<https://www.insudpharma.com/en/>) is a leading Spanish company with a track record in the pharmaceutical and healthcare industry spanning over 45 years. With 9,000 employees worldwide, Insud Pharma's contribution to global public health is enormous, thanks to the medicines and APIs developed and manufactured at its three highly synergic business units: industrial (Chemo), brand (Exeltis) and biotechnology (mAbxience).

Media Contacts

ASKA Pharmaceutical Holdings Co., Ltd.

Corporate Planning Department

Tel: +81-3-5484-8366

Email: kouhou@aska-pharma.co.jp